Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
322
datasets available to search
ShareScore release 0.9.0
Dataset results
322 results for “active ageing”
Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life
ClinicalTrials.gov study NCT01030419. IPD Sharing: NO. Countries: 1. Publications: 6.
Short and Mid-term Repeatability of Active Anterior Rhinomanometry (AAR) Measurements in Paediatric Age
ClinicalTrials.gov study NCT03286049. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Inhibition of Cdc42 activity extends lifespan and decreases circulating inflammatory cytokines in aged female C57BL/6 mice
Open the record for dataset details and reuse information.
Flight activity and age cause wing damage in house flies
Open the record for dataset details and reuse information.
Data from: Zinc supplementation inhibits complement activation in age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. AMD is a multifactorial disorder but complement-mediated inflammation at the level of the retina plays a pivotal role. Oral zinc supplementation can reduce the progression of AMD but the precise mechanism of this protective effect is as yet unclear. We investigated whether zinc supplementation directly affects the degree of complement activation in AMD and whether there is a relation between serum complement catabolism during zinc administration and the complement factor H (CFH) gene or the Age-Related Maculopathy susceptibility 2 (ARMS2) genotype. In this open-label clinical study, 72 randomly selected AMD patients in various stages of AMD received a daily supplement of 50 mg zinc sulphate and 1 mg cupric sulphate for three months. Serum complement catabolism–defined as the C3d/C3 ratio–was measured at baseline, throughout the three months of supplementation and after discontinuation of zinc administration. Additionally, downstream inhibition of complement catabolism was evaluated by measurement of anaphylatoxin C5a. Furthermore, we investigated the effect of zinc on complement activation in vitro. AMD patients with high levels of complement catabolism at baseline exhibited a steeper decline in serum complement activation (p<0.001) during the three month zinc supplementation period compared to patients with low complement levels. There was no significant association of change in complement catabolism and CFH and ARMS2 genotype. In vitro zinc sulphate directly inhibits complement catabolism in hemolytic assays and membrane attack complex (MAC) deposition on RPE cells. This study provides evidence that daily administration of 50 mg zinc sulphate can inhibit complement catabolism in AMD patients with increased complement activation. This could explain part of the mechanism by which zinc slows AMD progression.
Fig. 2 in Chemical constituents of Antidesma bunius aerial parts and the anti-AGEs activity of selected compounds
Fig. 2. Key HMBC (H→C) and 1H–1H COSY correlations of compounds 1–5, 8, 16, 17, and 20.
Fig. 1 in Chemical constituents of Antidesma bunius aerial parts and the anti-AGEs activity of selected compounds
Fig. 1. (continued).
Fig. 1 in Chemical constituents of Antidesma bunius aerial parts and the anti-AGEs activity of selected compounds
Fig. 1. Chemical structures of isolated compounds from A. bunius aerial parts.
Isometric Core Muscle Endurance in Healthy Active and Non-active Working Age Populations
ClinicalTrials.gov study NCT04209335. IPD Sharing: NO. Countries: 1. Publications: 0.
Exploring Temporal Relationships Between Self-worth and Physical Activity Middle-aged Women
ClinicalTrials.gov study NCT02332746. IPD Sharing: Not stated. Countries: 0. Publications: 9.
Physical Activity of Participants in Different Age Groups
ClinicalTrials.gov study NCT06622785. IPD Sharing: NO. Countries: 1. Publications: 0.
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
ClinicalTrials.gov study NCT05771428. IPD Sharing: YES. Countries: 7. Publications: 0.
Automatic Reaction to Physical Activity and Sedentary Stimuli in Aging
ClinicalTrials.gov study NCT05704660. IPD Sharing: NO. Countries: 0. Publications: 15.
School Intervention to Promote Physical Activity and Reduce the Sedentary Time of Low-income Children Aged 6-13 Years
ClinicalTrials.gov study NCT03983447. IPD Sharing: UNDECIDED. Countries: 0. Publications: 7.
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
ClinicalTrials.gov study NCT01134315. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for
ClinicalTrials.gov study NCT05068284. IPD Sharing: YES. Countries: 24. Publications: 0.
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
ClinicalTrials.gov study NCT05760313. IPD Sharing: YES. Countries: 7. Publications: 0.
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phen
ClinicalTrials.gov study NCT05731128. IPD Sharing: YES. Countries: 11. Publications: 0.
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
ClinicalTrials.gov study NCT05900154. IPD Sharing: NO. Countries: 1. Publications: 0.
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rh
ClinicalTrials.gov study NCT04888585. IPD Sharing: YES. Countries: 21. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.